Prostate and bladder cancer
C72 – C92
- C72: UK Urologists’ assessment and management of fracture risk in patients treated for prostate cancer
- C73: FGFR3 mutation is not the initiating mutation in urothelial cell cancer
- C74: β-Catenin induced senescence progresses to urothelial cell carcinoma with PTEN mutation
- C75: Developing dietary interventions for prostate cancer: systematic reviews and investigations of dietary change
- C76: Growth of a subset of human prostate epithelial cells can be inhibited by gonadotropin releasing hormone receptor activation
- C77: The ProtecT trial: evaluating the effectiveness of treatments for clinically localised prostate cancer
- C78: Expression of the endogenous signaling regulator Sef predicts prostate cancer behaviour and alters the cell response to targeted inhibition of FGF receptors.
- C79: Mutation analysis of the MSMB gene and its upstream region in familial prostate cancer
- C80: Protease nexin 1 and metal metalloproteinase 9 levels affect expression of hedgehog proteins in a prostate model of cancer
- C81: Effect of sulforaphane on global gene expression in a prostate-specific PTEN knockout mouse model
- C82: Manipulating androgen receptor cofactors as a therapeutic strategy for prostate cancer
- C83: Abstract withdrawn
- C84: Identification of multiple genetic variants which predispose to prostate cancer by genome-wide association in the PRACTICAL international consortium
- C85: Brca2 and Trp53 co-operate in the progression of mouse prostate neoplasia
- C86: Epigenetic regulation of the stem cell marker CD133 in prostate cancer
- C87: A double-blind, randomised, dose finding, phase II, multicentre study of Alpharadin® (radium-223) for the treatment of patients with metastatic castration-refractory prostate cancer (CRPC) EudraCT number: 2005-003680-22
- C88: CAP (comparison arm for ProtecT) trial: the design of a randomised controlled trial investigating the impact of population based prostate specific antigen (PSA) testing for prostate cancer
- C89: Identification of Androgen receptor gene expression signatures in prostate cancer with high through-put validation
- C90: Genetic profiling of prostate epithelial SP sub-populations
- C91: Arachidonic acid primes human bone marrow stroma for prostate cancer metastasis
- C92: Automated patient model construction and alignment to stereo video reconstructions for augmented reality guidance of robotic prostatectomy
